GSK3[beta] and the aging kidney

Kidney function decreases with age and may soon limit millions of lives as the proportion of the population over 70 years of age increases. Glycogen synthase kinase 3p (GSK3[beta]) is involved with metabolism and may have a role in kidney senescence, positioning it as a target for complications from...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 132; no. 4
Main Authors Kreidberg, Jordan A, Schumacher, Valerie A
Format Journal Article
LanguageEnglish
Published American Society for Clinical Investigation 15.02.2022
Online AccessGet full text

Cover

More Information
Summary:Kidney function decreases with age and may soon limit millions of lives as the proportion of the population over 70 years of age increases. Glycogen synthase kinase 3p (GSK3[beta]) is involved with metabolism and may have a role in kidney senescence, positioning it as a target for complications from chronic kidney disease. However, different studies suggest GSK3 has contrasting effects. In this issue of the JCI, Fang et al. explored the function of GSK3[beta] and the interplay with lithium using human tissue and mouse models. Notably, GSK3[beta] was overexpressed and activated in aging mice, and depleting GSK3[beta] reduced senescence and glomerular aging. In this Commentary, we explore the similarities and differences between Fang et al. and previous findings by Hurcombe et al. These findings should prompt further study of lithium and other GSK3[beta] inhibitors as a means of extending glomerular function in individuals with chronic kidney disease.
ISSN:0021-9738
1558-8238
DOI:10.1172/JCH55885